Marijuana Use in Adolescent Populations
To access this course, select Subscribe on the left. You will then be required to log-in or register if you do not already have an account.
The goal of this course is to enhance the knowledge of physicians and other healthcare providers about marijuana perceptions and usage among the adolescent populations. This module will also discuss the prevalence and long-term impacts marijuana usage may have on adolescent populations. By enhancing their knowledge, physicians and other healthcare providers can better assess patients who may suffer symptoms caused by marijuana use and provide informed guidance to their patients and caregivers regarding marijuana use.
- Recognize the basic pharmacology, pharmacokinetics, and methods of marijuana use
- Explain marijuana urine testing
- Discuss the prevalence of marijuana use among adolescents
- Describe the impacts marijuana may have on adolescents
- Identify strategies for communicating risk and providing guidance to adolescents and their parents
George Sam Wang, MD, FAAP
Assistant Professor of Pediatrics
Section of Emergency Medicine, Medical Toxicology
Department of Pediatrics
University of Colorado Anschutz Medical Campus, Children's Hospital Colorado
Dr. Wang, completed his pediatric residency and pediatric emergency medicine fellowship at Children's Hospital Colorado/Anschutz Medical Campus, and his medical toxicology fellowship at the Rocky Mountain Poison and Drug Center at Denver Health. He is an Assistant Professor of Pediatrics at Children's Hospital Colorado/Anschutz Medical Campus where he is a PEM and toxicology attending.
Approximate Completion Time
Continuing Education Information
This course qualifies as continuing education for physicians, nurses, certified health education specialists and other professionals provided by the Centers for Disease Control and its partners.
Origination Date – 06/30/2017
Expiration Date – 06/30/2019
1.0 CME (for physicians)
1.0 CME (attendance for non-physicians)
0.8 CNE (for nurses)
0.1 CEU (for other professionals)
CME activities with Joint Providers: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Centers for Disease Control and Prevention and the American College of Medical Toxicology. The Centers for Disease Control and Prevention is accredited by the (ACCME®) to provide medical education for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Centers for Disease Control and Prevention designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™.
CNE: The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the American Nurses Credentialing Center's Commission on Accreditation.
This activity provides 0.8 contact hours.
CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEU's for this program.
DISCLOSURE: In compliance with continuing education requirements, all presenters must disclose any financial or other associations with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters as well as any use of unlabeled product(s) or product(s) under investigational use.
CDC, our planners, content experts, and their spouses/partners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters with the exception of Carl Baum and he wishes to disclose that he serves as an expert witness in lead and mold medico-legal cases. These topics are discussed in the School Environment, Health, and Performance Course for which Dr. Baum served as a content reviewer and planner. And George Sam Wang and he wishes to disclose that he has written chapters on topics pertaining to marijuana, and is a CDPHE Med Marijuana Grant awardee, evaluating the pharmacokinctics of CBD in pediatric epilepsy patients.
Planning committee reviewed content to ensure there is no bias.
Content will not include any discussion of the unlabeled use of a product or a product under investigational use.
The Centers for Disease Control and Prevention and American College of Medical Toxicology are jointly providing the CNE for this activity.
CDC does not accept commercial support.
Acknowledgement: The U.S. Environmental Protection Agency (EPA) supports the PEHSU by providing partial funding to ATSDR under Inter-Agency Agreement number DW-75-95877701. Neither EPA nor ATSDR endorse the purchase of any commercial products or services mentioned in PEHSU publications.
- Marijuana Use in Adolescent Populations
- How To Obtain Continuing Education Credit